incurred the increased selling and administration expenses as aforesaid mentioned. In consideration of the net profit from operations in 1Q18, the Company's net profit margin to total revenue was 4.5% which
97.68 -15% % Net Profit / Total Revenue 18% 32% -14% % Net Profit excl. Disposal of Land / Revenue from Hospital Operations 19% 22% -3% Non-Controlling Interests 0.15 0.26 -43% Net Profit Attributable to
Consideration and Criterion Applied for Fixing the Value of Consideration Percent of the net tangible assets (NTA) Total Value of Consideration Size of Transaction ≤ 0.03% of NTA ≤ Baht 1,000,000 Small 0.03% of
from sale – net 713.46 682.57 30.89 4.53 705.29 676.49 28.80 4.26 2 For the 6-months period ended June 30, 2017, revenue from sale-net and total revenue grew at 4.26 percent and 5.01 percent respectively
, net profit of the company for the three-month ended 30 September 2018 is more than the total net profit of quarter 1 and quarter 2 of 2018 combined. For share of profit (loss) from investments in joint
net profit margin to total revenue was 0.83 percent. Performance of the Company and subsidiaries for 1st half Ending 30 Jun 2019 Revenue from Sales and Services In the first half of year 2019, the
new stores. As a result, the Company’s EBITDA margin to total revenues decreased from 12.78 percent to 12.03 percent. Net Profit In Q3 2019, the Company and subsidiaries had net profit from operations
ทุนที่มากกว่าดัชนีอ้างอิง (ดัชนี NASDAQ Biotechnology Net Total Return) ค่าธรรมเนียมการเก็บรักษาทรัพย์สิน (Depositary Fee) 0.015% ทั้งนี้ ค่าธรรมเนียมขั้นต่ าเดือนละ 1,200 ดอลลาร์สหรัฐอเมริกา ค่า
investors or high net worth investors, with a collective total amount not exceeding 50 million baht, at any given time. In any case, the number of bills offered shall not exceed a total of 10 bills at any
4,642.3 million when compared at the end of the year 2016 or up to 2.2%. Core assets comprise of loans to customers - net at 66.1% of total assets, followed by investments - net at 25.0% of total assets